Literature DB >> 4447920

Letter: Uncommon side effects of adriamycin (NSC-123127).

E Etcubanas, J R Wilbur.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4447920

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  8 in total

1.  Doxorubicin-induced hypotension in the beagle dog.

Authors:  E Herman; R Young; S Krop
Journal:  Agents Actions       Date:  1978-10

Review 2.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

3.  High incidence of local venous reactions to esorubicin.

Authors:  K M Lee; R T Dorr; A Robertone
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

4.  Locoregional interaction of ixabepilone (ixempra) after breast cancer radiation.

Authors:  Vinita Takiar; Eric A Strom; Donald P Baumann; Funda Meric-Bernstam; Ricardo H Alvarez; Ana M Gonzalez-Angulo
Journal:  Oncologist       Date:  2013-02-12

5.  Anthracycline-induced histamine release from rat mast cells.

Authors:  E A Riegel; M Kaliner; A N El-Hage; V J Ferrans; O Kawanami; E H Herman
Journal:  Agents Actions       Date:  1982-10

Review 6.  Radiation recall with anticancer agents.

Authors:  Howard A Burris; Jane Hurtig
Journal:  Oncologist       Date:  2010-11-02

7.  Radiation Recall Pneumonitis COVID-19 Infection Induced After Adjuvant Breast Cancer Radiotherapy. A Known Phenomenon in an Unknown Pandemic Disease: A Case Report.

Authors:  Grazia Lazzari; Renato Giua; Elisabetta Verdolino; Angela Pia Solazzo; Ilaria Benevento; Antonietta Montagna; Giovanni Castaldo; Luciana Rago; Giovanni Silvano
Journal:  Cancer Manag Res       Date:  2022-08-03       Impact factor: 3.602

8.  Radiation recall dermatitis: case report and review of the literature.

Authors:  A E Hird; J Wilson; S Symons; E Sinclair; M Davis; E Chow
Journal:  Curr Oncol       Date:  2008-01       Impact factor: 3.677
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.